Clinical studies demonstrated that sHLA-G levels were significantly elevated in sera of patients with malignant melanomas, gliomas, breast and ovarian cancers, non-small-cell-lung cancers (NSCLC), chronic lymphocytic leukemias, B cell and T cell Non-Hodgkin's lymphomas [17]–[21]. This evidence concerns the gene HLA-G and non-small cell lung carcinoma.